BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) is scheduled to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect BioXcel Therapeutics to post earnings of ($0.50) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

BioXcel Therapeutics Stock Performance

Shares of NASDAQ:BTAI opened at $0.67 on Wednesday. The business’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $1.09. The company has a market cap of $27.09 million, a P/E ratio of -0.19 and a beta of 0.29. BioXcel Therapeutics has a one year low of $0.51 and a one year high of $5.62.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BTAI. UBS Group dropped their price objective on shares of BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a research note on Friday, August 9th. HC Wainwright dropped their price target on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, October 21st. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price objective on shares of BioXcel Therapeutics in a research report on Friday, August 30th.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.